Filtered By:
Cancer: Lymphoma
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 275 results found since Jan 2013.
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
CONCLUSIONS: This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.PMID:37656225 | DOI:10.1080/13696998.2023.2254162
Source: Journal of Medical Economics - September 1, 2023 Category: Health Management Authors: Takashi Mizuoka Hiroyuki Sakamaki Shigeo Fuji Shota Saito Tatsunori Murata Shinya Ohno Naoki Inubashiri Tomoha Oshima Kazuhito Yamamoto Source Type: research
Trends in non-Hodgkin lymphoma mortality rate in Japan and the United States: A population-based study
Cancer Sci. 2023 Aug 18. doi: 10.1111/cas.15926. Online ahead of print.ABSTRACTCharacterizing trends in mortality rates with consideration of trends in incidence rates at the population level could help identify unmet needs in public health and provide essential indicators of cancer control. In the late 20th century, the arrival of the first molecular targeted agent, rituximab, for non-Hodgkin lymphoma (NHL) led to a paradigm shift in NHL treatment. However, the public health impact of this arrival has not been fully clarified. Here, we evaluated trends in the mortality and incidence rates of NHL in Japan and the United St...
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: Yoshiaki Usui Hidemi Ito Kota Katanoda Tomohiro Matsuda Yoshinobu Maeda Keitaro Matsuo Source Type: research
Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database
CONCLUSION: The incidence of malignant lymphoma in the combination therapy group was extensively higher than that in the general Japanese population. Special attention is required for early symptoms of malignant lymphoma, particularly in the 3rd - 4th year after initiating MTX therapy.PMID:37578124 | DOI:10.5414/CP204372
Source: Clinical Pharmacology and Therapeutics - August 14, 2023 Category: Drugs & Pharmacology Authors: Ryo Inose Arisa Nakamura Rina Omi Shujiro Takeno Yuichi Muraki Source Type: research
Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan
CONCLUSION: DUSP22 rearrangement is relatively specific to pcALCL among CD30-positive CTCLs in Japan. Although LEF1 expression pattern was not related with DUSP22 rearrangement in pcALCL, there was no rearrangement if LEF1 was not expressed. We confirmed that T3 stage and the lower limb involvement were significantly associated with the decreased OS and DSS. Presence or absence of lower limb lesions should better be included in T stage subcategory in the future.PMID:37539944 | DOI:10.1093/bjd/ljad266
Source: The British Journal of Dermatology - August 4, 2023 Category: Dermatology Authors: Tomomitsu Miyagaki Norihito Inoue Hiroaki Kamijo Hikari Boki Naomi Takahashi-Shishido Hiraku Suga Takatoshi Shimauchi Eiji Kiyohara Yoji Hirai Kentaro Yonekura Kengo Takeuchi Makoto Sugaya Source Type: research
Recent advances in treatment of nodal and gastrointestinal follicular lymphoma
World J Gastroenterol. 2023 Jun 21;29(23):3574-3594. doi: 10.3748/wjg.v29.i23.3574.ABSTRACTFollicular lymphoma (FL) is the most common low-grade lymphoma, and although nodal FL is highly responsive to treatment, the majority of patients relapse repeatedly, and the disease has been incurable with a poor prognosis. However, primary FL of the gastrointestinal tract has been increasingly detected in Japan, especially due to recent advances in small bowel endoscopy and increased opportunities for endoscopic examinations and endoscopic diagnosis. However, many cases are detected at an early stage, and the prognosis is good in ma...
Source: World Journal of Gastroenterology : WJG - July 3, 2023 Category: Gastroenterology Authors: Takuya Watanabe Source Type: research
